Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study

International Journal of Neuropsychopharmacology

Volumn 11, Issue 5, 2008, Pages 641-653

  Soyka, Michael ^a,b   Zingg, Christina ^b   Koller, Gabriele ^a   Kuefner, Heinrich ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Private Hospital Meiringen   (Switzerland)

^c Institute for Therapy Research   (Germany)

Author keywords

Buprenorphine; Drug dependence; Methadone; Outcome; Substitution

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; COCAINE; METHADONE;

ABSTINENCE; ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; COLD SENSATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; EUPHORIA; FATIGUE; FEAR; FEMALE; HEADACHE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MYDRIASIS; NAUSEA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; VOMITING; WITHDRAWAL SYNDROME;

ADULT; ANALYSIS OF VARIANCE; BUPRENORPHINE; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 41649092221     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570700836X     Document Type: Article

References (54)

1. Amass L, Kamien JB, Mikulich SK (2000). Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 58, 143-152.
2. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 28, 321-329.
3. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S (2004). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews. Issue 4. Art. No.: CD004147.
4. Barnett PG (1999). The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 94, 479-488.
5. Barnett PG, Rodgers JH, Bloch DA (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96, 683-690.
6. Bickel WK, Amass L, Crean JP, Badger GJ (1999). Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 146, 111-118.
7. Bradley BP, Gossop M, Phillips GT, Legarda JJ (1987). The development of an opiate withdrawal scale (OWS). British Journal of Addiction 82, 1139-1142.
8. Buehringer G, Kröger C, Küfner H, Lieb R, Schütz C, Soyka M, Wittchen H-U (2004). Substance abuse research network ASAT: allocating substance abuse to patient heterogenity [in German]. Suchtmedizin 6, 7-13.
9. Caplehorn JRM, Dalton MS, Haldar F, Petrenas AM, Nisbet JG (1996). Methadone maintenance and addicts' risk of fatal heroin overdose. Substance Use and Misuse 31, 177-196.
10. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS (2007). Methadone and buprenorphine for the management of opiod dependence: a systematic review and economic evaluation. Health Technology Assessment 11, 9.
11. Davids E, Gastpar M (2004). Buprenorphine in the treatment of opiod dependence. European Neuropsychopharmacology 14, 209-216.
12. Dolan KA, Shearer J, White B, Jialun Z, Kaldor J, Wodak AD (2005). Four-year follow-up of imprisoned male heroin users in methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 100, 820-828.
13. Farre M, Mas A, Torrens M, Moreno V, Carni J (2002). Retention rate and illicit opioids use during METH maintenance interventions; A meta-analysis. Drug and Alcohol Dependence 65, 283-290.
14. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS (2001). Methadone maintenance in primary care. Journal of the American Medical Association 286, 1724-1731.
15. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stühlinger G, Pezawas L, Aschauer HN, Kasper S (1999). Burprenorphinne versus methadone maintenance for opioid dependence. Addiction 94, 1337-1347.
16. Flynn PM, Joe GW, Broome KM, Simpson DD, Brown BS (2003). Recovery from opioid addiction in DATOS. Journal of Substance Abuse Treatment 25, 177-186.
17. Fugelstad A, Rajs J, Böttiger M, Gerhardsson de Verdier M (1995). Mortality among HIV-infected intravenous drug addicts in Stockholm in relation to methadone treatment. Addiction 90, 711-716.
18. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S (2004). Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence 75, 37-45.
19. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rössler H, Hinterhuber H, Kurz M (2003). Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 98, 693-702.
20. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N (2003). A comparison of buprenorphine treatment in clinic and primary care settings: a randomized trial. Medical Journal of Australia 179, 38-42.
21. Gowing L, Ali R, White J (2006). Buprenorphine for the management of opiod withdrawal. Cochrane Database of Systematic Reviews. Issue 2. Art. No.: CD002025.
22. Gsellhofer B, Küfner H, Vogt M, Weiler D (1999). European Addiction Severity Index, EuropASI. Manual für Training und Durchführung von Interviews mit dem EuropASI. Baltmannsweiler: Schneider.
23. Hser YI, Hoffman V, Grella CE, Anglin MD (2001). A 33-year follow-up of narcotics addicts. Archives of General Psychiatry 58, 503-508.
24. Hulse GK, English DR, Milne E, Holman CDJ (1999). The quantification of mortality resulting from the regular use of illicit opiates. Addiction 94, 221-229.
25. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 343, 1290-1297.
26. King VL, Stoller KB, Hayes M, Umbricht A, Currens M, Kidorf MS, Carter JA, Schwartz R, Brooner RK (2002). A multicenter randomized evaluation of methadone medical maintenance. Drug and Alcohol Dependence 65, 137-148.
27. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J (1993). Buprenorphine versus METH maintenance for opioids dependence. Journal of Nervous and Mental Disease 181, 358-364.
28. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ (2001). The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health 91, 774-780.
29. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, et al. (1998). Buprenorphine maintenance treatment of opiate dependence: multicenter, randomized clinical trial. Addiction 93, 475-486.
30. Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G (2004). Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. American Journal of Addiction 13 (Suppl. 1), 29-41.
31. Mattick RP, Kimber J, Breen C, Davoli M (2004). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. Issue 1. Art. No.: CD002207.
32. Mattick RP, White JM, O'Brien S, Wolk S, Danz C (2003). Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 98, 441-452.
33. Maxwell JC, Pullum TW, Tannert K (2005). Deaths of Clients in methadone treatment in Texas: 1994-2002. Drug and Alcohol Dependence 78, 73-81.
34. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ (2004). Randomized trial of burprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics 75, 34-38.
35. Newman RG (1987). Methadone treatment. New England Journal of Medicine 317, 447-450.
36. O'Brien CP (1994). Overview: the treatment of drug dependence. Addiction 89, 1565-1569.
37. O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS (1998). A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine 105, 100-105.
38. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL (2000). Buprenorphine: a controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence 60, 39-50.
39. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D (2001). Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence 62, 97-104.
40. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I (2004). A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99, 978-988.
41. Plomp HN, Van der Hek H, Ader HJ (1996). The Amsterdam methadone dispensing circuit: Genesis and effectiveness of a public health model for local drug politics. Addiction 91, 711-721.
42. Schottenfeld RS, Pakes JR, Kosten TR (1998). Prognostic factors in buprenorphine- versus methadone-maintained patients. Journal of Nervous and Mental Disease 186, 35-43.
43. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H (2005). Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients. Journal of Clinical Psychopharmacology 25, 1-4.
44. Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994a). Comparison of buprenorphine and methadone for the treatment of opioid dependent cocine users. Psychopharmacology 116, 401-406.
45. Strain EC, Stitzner ML, Liebson IA, Bigelow GE (1994b). Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 151, 569-580.
46. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA (2005). Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 100, 150-158.
47. Termorshuizen F, Krol A, Prins M, van Ameijden EJC (2005). Long-term outcome of chronic drug use. American Journal of Epidemiology 161, 271-279.
48. United Nations Office for Drug Control (2005). World Illicit Drug Report 2005. New York: United Nations Publications.
49. Van den Brink W, Hendriks VM, Blanken P, Koeter MWJ, van Zwieten B, van Ree JM (2003). Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. British Medical Journal 327, 310-316.
50. Van den Brink W, Haasen C (2006). Evidence-based treatment of opioid-dependent patients. Canadian Journal of Psychiatry 51, 635-646.
51. Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, De Chiara M, Corrado F, Cocchi L, Cozzolino E (2006). Multimodal drug addiction treatment. A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. Journal of Substance Abuse Treatment 31, 3-7.
52. Vormfelde SV, Poser Z (2001). Death attributed to methadone. Pharmacopsychiatry 34, 217-222.
53. West SL, O'Neal KK, Graham CW (2000). A meta-analysis comparing the effectiveness of buprenorphine and methadone. Journal of Substance Abuse 12, 405-414.
54. White JM, Lopatko OV (2007). Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy 8, 1-11.